Chapter 1 of 25
- Cervical lining
- Precancer stays within the lining
- Invasion reaches deeper tissue
- Examination, biopsy and staging guide care
What you will learn
Recognize the cervix and transformation zone; distinguish precancer from invasive cancer; understand why the exact tissue diagnosis matters.
The cervix and its changing lining
The uterus is the muscular organ where a pregnancy grows. Its upper cavity is lined by the endometrium; endometrial cancer is a different disease. The cervix forms a narrow passage between that cavity and the vagina. The visible outer cervix is mostly covered by flat squamous cells. The canal contains mucus-producing glandular cells. The transformation zone is the area where one lining changes into the other. Its position changes with age, hormones and menopause, sometimes moving into the canal where it is harder to see.
Most HPV-related cervical precancers arise around this junction. A speculum gently separates the vaginal walls so a clinician can see the cervix; it does not enter the uterus. Sampling may need to include the canal if the relevant area is not visible. A normal-looking cervix does not exclude microscopic changes.
From altered cells to invasion
Precancer means abnormal cells remain within the surface lining. Cervical intraepithelial neoplasia, or CIN, describes squamous precancer; adenocarcinoma in situ, or AIS, describes a glandular precancer. These conditions are not the same as invasive cancer, and their management often avoids major cancer treatment. Some low-grade changes regress. High-grade changes need reliable surveillance or treatment because their risk is greater.
Invasive cancer has crossed the lining's supporting boundary into deeper tissue. It can grow locally or reach lymph nodes and, sometimes, distant organs. A biopsy establishes invasion; an HPV test alone cannot. Symptoms and screening results cannot reliably tell how deep disease extends.
Different tissue types
Squamous cell carcinoma develops from squamous cells. Adenocarcinoma develops from glandular cells and can be less readily visible in the canal. Adenosquamous cancers contain both components. Uncommon neuroendocrine cancers and HPV-independent adenocarcinomas, including gastric-type disease, may behave differently and require specialist pathology and treatment planning. Do not assume that every cervical tumour follows the common squamous-cancer pathway.
The pathology report identifies the histological type. Stage describes where cancer has spread; grade describes microscopic appearance. These are different measurements. Neither the size of a biopsy fragment nor the presence of HPV alone determines the stage.
A practical first appointment
Ask for a copy of the pathology report and the exact diagnosis in ordinary language. Clarify whether the finding is HPV infection, a screening abnormality, precancer or invasive cancer. If cancer is confirmed, the next steps may include specialist examination, imaging and a multidisciplinary discussion. Treatment decisions depend on those results, fertility wishes and overall health, rather than the word “cancer” alone.
People of any gender who have a cervix can need cervical care. Ask for respectful language, a chaperone, an interpreter or a clinician you feel comfortable with. You may request an explanation before each part of an examination and ask to pause.
Misconception and common question
“Precancer means cancer has already spread” is incorrect. Precancer remains in the lining. Does a hysterectomy always follow? No: many precancers and some very early cancers can be managed with a smaller procedure, after appropriate assessment.
Take-home messages
Know the exact tissue diagnosis. Keep screening, diagnosis and staging separate. Bring questions about fertility and examination comfort early, before choosing treatment.
References and review status
- NCI — Cervical cancer treatment PDQ (professional evidence summary)
- Bhatla et al. Cancer of the cervix uteri: FIGO Cancer Report 2025
- Cibula et al. ESGO/ESTRO/ESP cervical cancer guidelines, 2023 update
Evidence/editorial check: 28 October 2026. AI-assisted preparation is separate from physician sign-off. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.
Evidence scope and update policy